Carl Zeiss Meditec AG (XBUL:AFX) LT-Debt-to-Total-Asset: 0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XBUL:AFX Carl Zeiss Meditec AG XBUL:AFX
71 GF Score
Price лв42.34
GF Value лв98.20
! 3 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG LT-Debt-to-Total-Asset?

Carl Zeiss Meditec AG XBUL:AFX 71 LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus rates XBUL:AFX with a GF Score™ of 71/100 and a GF Value™ of лв98.20. The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Carl Zeiss Meditec AG's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.00.

Carl Zeiss Meditec AG's long-term debt to total assets ratio stayed the same from Dec. 2024 (0.00) to Dec. 2025 (0.00).

Carl Zeiss Meditec AG  (XBUL:AFX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Carl Zeiss Meditec AG LT-Debt-to-Total-Asset Related Terms

Carl Zeiss Meditec AG LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG LT-Debt-to-Total-Asset Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.04 0.04 0.04 0.03

Carl Zeiss Meditec AG Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.04 0.00 0.03 0.00
XBUL:AFX
71GF Score
Carl Zeiss Meditec AG XBUL:AFX
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carl Zeiss Meditec AG LT-Debt-to-Total-Asset Calculation

Carl Zeiss Meditec AG's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as

LT Debt to Total Assets (A: Sep. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Sep. 2025 )/Total Assets (A: Sep. 2025 )
=218.353/6860.697
=0.03

Carl Zeiss Meditec AG's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=0/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Carl Zeiss Meditec AG (XBUL:AFX) has a LT-Debt-to-Total-Asset of 0.00 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Carl Zeiss Meditec AG and its competitors.
Is Carl Zeiss Meditec AG's LT-Debt-to-Total-Asset too high?
Carl Zeiss Meditec AG's current LT-Debt-to-Total-Asset is 0.00. Overall, Carl Zeiss Meditec AG has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's LT-Debt-to-Total-Asset compare to ISRG and BDX?
Carl Zeiss Meditec AG's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Carl Zeiss Meditec AG (XBUL:AFX) has a current LT-Debt-to-Total-Asset of 0.00. The stock's GF Value™ is лв98.20, compared to a current price of лв42.34 — trading 56.9% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Carl Zeiss Meditec AG's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XBUL:AFX), the current LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (XBUL:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of лв42.34 is trading 56.9% below its estimated GF Value™ of лв98.20.

Key valuation signals for XBUL:AFX:

  • LT-Debt-to-Total-Asset: 0.00
  • GF Value™: лв98.20 vs. price of лв42.34 (56.9% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the XBUL:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
71GF Score

Get the complete analysis for XBUL:AFX

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

лв42.34
Price
лв98.20
GF Value